454.93
Alnylam Pharmaceuticals Inc (ALNY) 財務データ
損益計算書
四半期ごと
*すべての数値は百万単位です
期間終了日 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
期間の長さ | 3 か月 | 3 か月 | 3 か月 | 3 か月 | 3 か月 |
Revenues |
30.21%
773.69
|
594.19 | 593.17 | 500.92 | 659.83 |
Cost Of Revenue |
102.37%
142.03
|
70.18 | 102.65 | 81.98 | 67.27 |
Gross Profit |
20.54%
631.66
|
524.01 | 490.52 | 418.94 | 592.55 |
|
28.05%
647.86
|
505.93 | 595.68 | 495.84 | 543.94 |
Benefits Costs and Expenses |
27.25%
809.05
|
635.78 | 787.12 | 609.58 | 670.99 |
Costs And Expenses |
37.11%
789.89
|
576.11 | 698.33 | 577.82 | 611.21 |
Operating Income/Loss |
189.61%
-16.20
|
18.08 | -105.16 | -76.91 | 48.61 |
Nonoperating Income/Loss |
67.89%
-19.16
|
-59.67 | -88.80 | -31.76 | -59.78 |
Income/Loss From Continuing Operations Before Tax |
15.00%
-35.36
|
-41.60 | -193.96 | -108.66 | -11.17 |
Income Tax Expense/Benefit, Deferred |
1.00%
9.735
|
9.639 | - | - | - |
Income Tax Expense/Benefit |
94.67%
30.92
|
15.88 | -110.19 | 2.907 | 5.722 |
Income/Loss From Continuing Operations After Tax |
15.31%
-66.28
|
-57.48 | -83.76 | -111.57 | -16.89 |
|
15.31%
-66.28
|
-57.48 | -83.76 | -111.57 | -16.89 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
0.73%
130.63
|
129.68 | 0.492 | 128.59 | 126.73 |
Diluted Average Shares |
0.73%
130.63
|
129.68 | 0.492 | 128.59 | 126.73 |
Basic Earnings Per Share |
15.91%
-0.51
|
-0.44 | -0.65 | -0.87 | -0.13 |
Diluted Earnings Per Share |
15.91%
-0.51
|
-0.44 | -0.65 | -0.87 | -0.13 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
大文字化:
|
ボリューム (24 時間):